P 113D

Drug Profile

P 113D

Alternative Names: P-113 pulmonary spray - Demegen; P113D

Latest Information Update: 25 Feb 2008

Price : $50

At a glance

  • Originator Demegen
  • Class Amino acids; Antibacterials; Antifungals; Peptide antibiotics; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections

Highest Development Phases

  • Discontinued Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 27 Jun 2003 Suspended - Preclinical for Cystic fibrosis-associated respiratory tract infections in USA (Inhalation)
  • 05 Nov 2002 P 113D has received orphan drug status for Cystic fibrosis in USA
  • 03 Apr 2002 Preclinical trials in Cystic fibrosis-associated respiratory tract infections in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top